Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

In vitro discovery and optimization of a human monoclonal antibody that neutralizes neurotoxicity and lethality of cobra snake venom

View through CrossRef
Abstract The monocled cobra ( Naja kaouthia ) is one of the most feared snakes in Southeast Asia. It is a highly dangerous species with a potent venom deriving its toxicity predominantly from abundant long-chain α-neurotoxins. The only specific treatment for snakebite envenoming is antivenom, which is based on animal-derived polyclonal antibodies. Despite the lifesaving importance of these medicines over the past 120 years, and their ongoing role in combating snakebite disease, major limitations in safety, supply consistency, and efficacy creates a need for a new generation of improved treatments based on modern biotechnological techniques. Here, we describe the initial discovery and subsequent optimization of a recombinant human monoclonal immunoglobin G (IgG) antibody against α-cobratoxin using phage display technology. Affinity maturation of the parental antibody by light chain-shuffling resulted in an 8-fold increase in affinity, translating to a significant increase in in vitro neutralization potency and in vivo efficacy. While the parental antibody prolonged survival of mice challenged with purified α-cobratoxin, the optimized antibody prevented lethality when incubated with N. kaouthia whole venom prior to intravenous injection. This study is the first to demonstrate neutralization of whole snake venom by a single recombinant monoclonal antibody. Importantly, this suggests that for venoms whose toxicity relies on a single predominant toxin group, such as that of N. kaouthia , as little as one monoclonal antibody may be sufficient to prevent lethality, thus providing a tantalizing prospect of bringing recombinant antivenoms based on human monoclonal or oligoclonal antibodies to the clinic. One Sentence Summary A recombinant human monoclonal immunoglobulin G antibody, discovered and optimized using in vitro methods, was demonstrated to neutralize the lethal effect of whole venom from the monocled cobra in mice via abrogation of α-neurotoxin-mediated neurotoxicity.
Title: In vitro discovery and optimization of a human monoclonal antibody that neutralizes neurotoxicity and lethality of cobra snake venom
Description:
Abstract The monocled cobra ( Naja kaouthia ) is one of the most feared snakes in Southeast Asia.
It is a highly dangerous species with a potent venom deriving its toxicity predominantly from abundant long-chain α-neurotoxins.
The only specific treatment for snakebite envenoming is antivenom, which is based on animal-derived polyclonal antibodies.
Despite the lifesaving importance of these medicines over the past 120 years, and their ongoing role in combating snakebite disease, major limitations in safety, supply consistency, and efficacy creates a need for a new generation of improved treatments based on modern biotechnological techniques.
Here, we describe the initial discovery and subsequent optimization of a recombinant human monoclonal immunoglobin G (IgG) antibody against α-cobratoxin using phage display technology.
Affinity maturation of the parental antibody by light chain-shuffling resulted in an 8-fold increase in affinity, translating to a significant increase in in vitro neutralization potency and in vivo efficacy.
While the parental antibody prolonged survival of mice challenged with purified α-cobratoxin, the optimized antibody prevented lethality when incubated with N.
kaouthia whole venom prior to intravenous injection.
This study is the first to demonstrate neutralization of whole snake venom by a single recombinant monoclonal antibody.
Importantly, this suggests that for venoms whose toxicity relies on a single predominant toxin group, such as that of N.
kaouthia , as little as one monoclonal antibody may be sufficient to prevent lethality, thus providing a tantalizing prospect of bringing recombinant antivenoms based on human monoclonal or oligoclonal antibodies to the clinic.
One Sentence Summary A recombinant human monoclonal immunoglobulin G antibody, discovered and optimized using in vitro methods, was demonstrated to neutralize the lethal effect of whole venom from the monocled cobra in mice via abrogation of α-neurotoxin-mediated neurotoxicity.

Related Results

Cobra Venom Factor: Evidence for Its Being Altered Cobra C3 (the Third Component of Complement)
Cobra Venom Factor: Evidence for Its Being Altered Cobra C3 (the Third Component of Complement)
Evidence is presented that cobra venom factor, the anticomplementary protein in Naja naja venom, is modified cobra C3 (the third component of complement). A...
Integrative multi-omics analysis reveals the contribution of neoVTX genes to venom diversity of Synanceia verrucosa
Integrative multi-omics analysis reveals the contribution of neoVTX genes to venom diversity of Synanceia verrucosa
Abstract Background Animal venom systems have been considered as valuable model for investigating molecular mechanisms underlying phenotypic evolution. The stonefish were ...
Medicinal potentials of snake venom components: A review
Medicinal potentials of snake venom components: A review
Over the last several decades, research on snake venom toxins has provided not only new tools to decipher molecular details of various physiological processes, but also inspiration...
Viper Venom and Synthetic Peptides: Emerging Active Ingredients in Anti-Ageing Cosmeceuticals
Viper Venom and Synthetic Peptides: Emerging Active Ingredients in Anti-Ageing Cosmeceuticals
The animal kingdom, particularly reptiles, is widely recognized as a valuable source of peptides and proteins with applications in medicine, the pharmaceutical industry and, more r...
New RP-HPLC Method for Separation of Naja haje haje Venom and Studies of its Bactericidal Effect
New RP-HPLC Method for Separation of Naja haje haje Venom and Studies of its Bactericidal Effect
Abstract Background: Snake venom is a complex mixture of biologically active substances. Some peptides and proteins from snake have already demonstrated their the...
The role of component-resolved diagnosis in Hymenoptera venom allergy in clinical practice
The role of component-resolved diagnosis in Hymenoptera venom allergy in clinical practice
Background: Hymenoptera venom allergy is an immunoglobulin (Ig) E mediated hypersensitivity reaction to Hymenoptera venoms. Obvious identification of the culprit insect that causes...

Back to Top